Q-omics provides the consensus-scored MAP3K20 profile across patient tissues and cancer cell-line models. MAP3K20 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MAP3K20 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, MAP3K20 RNA expression shows 20,075 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where MAP3K20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP3K20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP3K20 survival associations across molecular data types. MAP3K20 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP3K20 RNA expression–survival associations across cancer types. High MAP3K20 expression shows unfavorable associations in UVM, MESO, ACC, LGG, KIRP and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MAP3K20 RNA expression.
This table summarizes MAP3K20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAP3K20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP3K20 shows lower tumor expression in BLCA, UCEC, BRCA and LUAD and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher MAP3K20 RNA expression in tumor versus normal tissue (log2 FC = +0.980, t-test p < 0.001).
This table shows molecular features associated with MAP3K20 in patient tissues and cancer cell lines. In patient samples, MAP3K20 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP3K20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
